TRICIDA, INC.
Presenter SpeechGeoffrey Parker (Executives)Good morning, ladies and gentlemen. I'm Geoff Park...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Tricida, Inc. is a pharmaceutical company. The Company is focused on its investigational drug candidate, veverimer (TRC101). TRC101 is a non-absorbed, orally administered polymer designed to treat metabolic acidosis and slow CKD progression by binding and removing acid from the gastrointestinal (GI) tract. Its veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. Veverimer is a single, high molecular weight, crosslinked polyamine molecule. The size of veverimer prevents systemic absorption from the GI tract. The high degree of cross-linking within veverimer limits swelling and the overall volume in the GI tract, with the goal of facilitating GI tolerability. It is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD.
| 1st Jan change | Capi. | |
|---|---|---|
| +40.50% | 54.04B | |
| +45.55% | 41.96B | |
| -1.30% | 41.92B | |
| -7.20% | 28.35B | |
| +12.49% | 26.35B | |
| -21.12% | 19B | |
| +6.66% | 13B | |
| +29.02% | 12.28B | |
| +25.95% | 12.19B |
